A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 928 participants.

Also called NCT05362058

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 928 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05362058
  • EudraCT 2021-005891-21
Other papers using this trial's data
  • Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment The New England journal of medicine, 2024-12-12 DOI, PubMed 39254740

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Brazil, Canada, China, Czechia, Germany, Greece, Japan, Mexico, Puerto Rico, South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05362058. Randomized; no masking; primary purpose treatment. Start 2022-06-03 (actual); primary completion 2024-04-10 (actual). Results posted on 2025-05-16.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time
Acronym
QWINT-2
Condition
Diabetes
Intervention (Drug)
Insulin Efsitora Alfa
Intervention (Drug)
Insulin Degludec
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct05362058
Content hash
d19f70d68f684b7950e5d13da53747a61f44076c5f5282c53655706e8d8021a4